Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Merck’s experimental HIV drug proves effective and well tolerated
Updating previous, similar findings, researchers have now reported on 96-week data from a pair of ongoing trials.
This finding did not vary based on the dose of the nucleoside reverse transcriptase translocation inhibitor, formerly called MK-8591.
The Food and Drug Administration has approved a new treatment for people living with HIV.
Research in human cells and mice found the antiretroviral suppressed harmful chronic inflammation linked to age-related disorders.
In clinical trials, the single-tablet regimen of Tivicay (dolutegravir) and Epivir (lamivudine) was as effective as a three-drug treatment.
Full 48-week results comparing dolutegravir plus lamivudine with a three-drug combo were presented at the International AIDS Conference.
The FDA approves three new, cheaper combination ARV tablets.
The combo of dolutegravir and lamivudine controlled HIV as well as a triple-drug combo of dolutegravir plus Truvada.
Symfi Lo contains efavirenz, lamivudine and tenofovir disoproxil fumarate (TDF); Cimduo contains TDF and lamivudine.
The trial will test a regimen of Tivicay (dolutegravir) plus Epivir (lamivudine) against Tivicay and Truvada (tenofovir/emtricitabine).
The regimen of Tivicay (dolutegravir) and Epivir (lamivudine) would be a highly cost-effective first-line option and save a great deal.
HIV-positive women who breastfeed can protect their infants from infection for a year after birth by giving them a liquid form of PrEP.
A two-drug regimen of Norvir (ritonavir)Ã¢€“boosted Reyataz (atazanavir) and Epivir (lamivudine) treats HIV as well or better tha...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.